Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (Weighted Average): 2018-2025

Historic Shares Outstanding (Weighted Average) for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $47.1 million.

  • Whitehawk Therapeutics' Shares Outstanding (Weighted Average) rose 91.46% to $47.1 million in Q3 2025 from the same period last year, while for Mar 2025 it was $46.8 million, marking a year-over-year increase of 90.54%. This contributed to the annual value of $24.6 million for FY2024, which is 0.50% up from last year.
  • Whitehawk Therapeutics' Shares Outstanding (Weighted Average) amounted to $47.1 million in Q3 2025, which was up 0.04% from $47.1 million recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $47.1 million for Q3 2025, and its period low was $3.2 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $30.7 million, with a median of $24.6 million in 2024.
  • Data for Whitehawk Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 565.25% (in 2021) over the last 5 years.
  • Over the past 5 years, Whitehawk Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $20.9 million in 2021, then climbed by 16.76% to $24.4 million in 2022, then climbed by 0.54% to $24.5 million in 2023, then increased by 0.50% to $24.6 million in 2024, then soared by 91.46% to $47.1 million in 2025.
  • Its last three reported values are $47.1 million in Q3 2025, $47.1 million for Q2 2025, and $46.8 million during Q1 2025.